×
About 6,325 results

ALLMedicine™ Familial Hypercholesterolemia Center

Research & Reviews  2,693 results

Investigation of the underlying genes and mechanism of familial hypercholesterolemia th...
https://doi.org/10.1186/s12872-020-01701-z
BMC Cardiovascular Disorders; Wang D, Liu B et. al.

Sep 17th, 2020 - Familial hypercholesterolemia (FH) is one of the commonest inherited metabolic disorders. Abnormally high level of low-density lipoprotein cholesterol (LDL-C) in blood leads to premature atherosclerosis onset and a high risk of cardiovascular dise...

Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low d...
https://doi.org/10.1016/j.atherosclerosis.2020.08.002
Atherosclerosis Rodríguez-Nóvoa S, Rodríguez-Jiménez C et. al.

Sep 16th, 2020 - Familial hypercholesterolemia is most frequently caused by genetic variants in the LDLR gene. Most of LDLR pathogenic variants are missense, followed by splicing and deletion/insertions variants. Mosaicism is a genetic condition in which an indivi...

Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with...
https://doi.org/10.12659/AJCR.923722
The American Journal of Case Reports; Matta A, Taraszkiewicz D et. al.

Sep 15th, 2020 - BACKGROUND Real-life data on the efficacy of monotherapy with PCSK9 inhibitors are scarce. Most cohort studies have examined populations that are not severely dyslipidemic and are receiving combined therapy rather than monotherapy. CASE REPORT Fro...

Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the athero...
https://doi.org/10.1093/cvr/cvaa264
Cardiovascular Research; Bonacina F, Martini E et. al.

Sep 15th, 2020 - Loss of immunosuppressive response supports inflammation during atherosclerosis. We tested whether adoptive cell therapy (ACT) with Tregulatory cells (Tregs) engineered to selectively migrate in the atherosclerotic plaque would dampen the immune-i...

Electronic health records to facilitate continuous detection of familial hypercholester...
https://doi.org/10.1016/j.atherosclerosis.2020.07.022
Atherosclerosis Pepplinkhuizen S, Ibrahim S et. al.

Sep 14th, 2020 - Familial hypercholesterolemia (FH) is an inherited disorder associated with increased risk of coronary heart disease as a result of high LDL-cholesterol (LDL-C). The clinical diagnosis can be made with the Dutch Lipid Clinic Network criteria (DLCN...

see more →

Guidelines  9 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Screening for Lipid Disorders in Children and Adolescents: Clinical Summary
https://allmedx.com/USPSTFPDF/lipidscreening_ch-summary.pdf

Aug 2nd, 2016 - Figure. Screening for Lipid Disorders in Children and Adolescents: Clinical Summary Population Asymptomatic children and adolescents 20 years or younger Recommendation No recommendation. Grade: I (insufficient evidence) Ri...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 17th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

NEXLETOL™ (bempedoic acid) - A New Treatment Option‎
https://www.nexletolhcp.com/

Discover How NEXLETOL May Help Appropriate Patients. See Important Safety Information and Full Prescribing Information. Learn About New Treatment. FDA Approved. Get The Facts.

see more →

Drugs  317 results see all →

Clinicaltrials.gov  3,129 results

Investigation of the underlying genes and mechanism of familial hypercholesterolemia th...
https://doi.org/10.1186/s12872-020-01701-z
BMC Cardiovascular Disorders; Wang D, Liu B et. al.

Sep 17th, 2020 - Familial hypercholesterolemia (FH) is one of the commonest inherited metabolic disorders. Abnormally high level of low-density lipoprotein cholesterol (LDL-C) in blood leads to premature atherosclerosis onset and a high risk of cardiovascular dise...

Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low d...
https://doi.org/10.1016/j.atherosclerosis.2020.08.002
Atherosclerosis Rodríguez-Nóvoa S, Rodríguez-Jiménez C et. al.

Sep 16th, 2020 - Familial hypercholesterolemia is most frequently caused by genetic variants in the LDLR gene. Most of LDLR pathogenic variants are missense, followed by splicing and deletion/insertions variants. Mosaicism is a genetic condition in which an indivi...

Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with...
https://doi.org/10.12659/AJCR.923722
The American Journal of Case Reports; Matta A, Taraszkiewicz D et. al.

Sep 15th, 2020 - BACKGROUND Real-life data on the efficacy of monotherapy with PCSK9 inhibitors are scarce. Most cohort studies have examined populations that are not severely dyslipidemic and are receiving combined therapy rather than monotherapy. CASE REPORT Fro...

Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the athero...
https://doi.org/10.1093/cvr/cvaa264
Cardiovascular Research; Bonacina F, Martini E et. al.

Sep 15th, 2020 - Loss of immunosuppressive response supports inflammation during atherosclerosis. We tested whether adoptive cell therapy (ACT) with Tregulatory cells (Tregs) engineered to selectively migrate in the atherosclerotic plaque would dampen the immune-i...

Electronic health records to facilitate continuous detection of familial hypercholester...
https://doi.org/10.1016/j.atherosclerosis.2020.07.022
Atherosclerosis Pepplinkhuizen S, Ibrahim S et. al.

Sep 14th, 2020 - Familial hypercholesterolemia (FH) is an inherited disorder associated with increased risk of coronary heart disease as a result of high LDL-cholesterol (LDL-C). The clinical diagnosis can be made with the Dutch Lipid Clinic Network criteria (DLCN...

see more →

News  173 results

New lipid-lowering drug class slashes LDL in HoFH patients
https://www.mdedge.com/fedprac/article/219837/lipid-disorders/new-lipid-lowering-drug-class-slashes-ldl-hofh-patients?channel=53
Mitchel L. Zoler

Mar 30th, 2020 - Evinacumab, the first agent from a new class of lipid-lowering drugs, showed a “remarkable” and unprecedented level of LDL-cholesterol lowering in a pivotal trial with 65 patients with homozygous familial hypercholesterolemia. Dr.

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

New lipid-lowering drug earns FDA approval
https://www.mdedge.com/jcomjournal/article/217680/lipid-disorders/new-lipid-lowering-drug-earns-fda-approval?channel=39313
Patrice Wendling

Feb 21st, 2020 - The Food and Drug Administration has approved bempedoic acid (Nexletol) for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL cho.

Statins cut long-term CVD risk in kids with familial hypercholesterolemia
https://www.mdedge.com/internalmedicine/article/212063/lipid-disorders/statins-cut-long-term-cvd-risk-kids-familial?channel=39313
Andrew D. Bowser

Nov 11th, 2019 - Statins started in childhood for patients with familial hypercholesterolemia reduced progression of carotid thickening and cut the risk of cardiovascular disease 20 years later, according to authors of a long-term follow-up study. There were no de.

Aortic Stenosis in FH; Plaque Erosion; CAD Wave Intensity Analysis
https://www.medpagetoday.com/cardiology/pci/82923

Oct 24th, 2019 - Familial hypercholesterolemia comes with higher risk of aortic stenosis compared to the general population, according to a Norwegian registry study. Whether early initiation of LDL cholesterol-lowering therapy could prevent aortic stenosis might b...

see more →

Patient Education  4 results see all →